Free shipping on all orders over $ 500

Cilastatin

Cat. No. M6090
Cilastatin Structure
Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM/1mL In DMSO USD 110 In stock
10mg USD 90 In stock
50mg USD 380 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Cilastatin attenuates VAN-induced acute renal failure in vitro by decreasing apoptosis without affecting antibacterial activity. This effect could be related, at least in part, to the reduction in accumulation of the drug in cells. Therefore, cilastatin could represent a novel therapeutic approach in reducing VAN-induced renal damage without compromising bactericidal efficacy.

Protocol
Cell Experiment
Cell lines Proximal Tubular Primary Cell
Preparation method Cells were pretreated with VAN (0.6, 3, and 6 mg/mL) alone or in combination with cilastatin (200 μg/mL) before being trypsinized, washed twice with PBS, and incubated for 30 min in the dark in 100 μL buffer containing 5 μL fluorescein isothiocyanate- (FITC-) labeled annexin V and 5 μL PI for flow cytometry.
Concentrations 200 μg/mL
Incubation time 24 h
Animal Experiment
Animal models
Formulation
Dosages
Administration
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 358.45
Formula C16H26N2O5S
CAS Number 82009-34-5
Purity 99.71%
Solubility 10 mM in DMSO
Storage at -20°C
References

Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity.
Humanes B, et al. Biomed Res Int. 2015;2015:704382. PMID: 26504822.

Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
Ramirez J, et al. Antimicrob Agents Chemother. 2013 Apr;57(4):1756-62. PMID: 23357775.

Related Products
LY2334737

LY2334737 is an orally available valproic acid ester of gemcitabine, a broad-spectrum antimetabolite with antineoplastic activity.

TUG-891

TUG-891 is a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120).

GSK2981278

GSK2981278 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma).

EXP-3174

EXP-3174 is a potent AT1 antagonist with Kis of 0.57 and 0.67 nM for rat and human forms, respectively.

NAV-2729

NAV-2729 is a selective ARF6 inhibitor with IC50 value of 1.0 μM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Cilastatin supplier, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.